Actively Recruiting
Clinical Trial of PEEL-224 Alone and With Vincristine and Temozolomide for Children and Young Adults With Refractory or Relapsed Solid Tumors
Led by Theodore Laetsch · Updated on 2026-10-06
59
Participants Needed
7
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating PEEL-224, a new drug, alone and combined with vincristine and temozolomide in children and young adults aged 1 to 30 years with difficult-to-treat, relapsed, or progressive solid tumors, including neuroblastoma and rhabdomyosarcoma. This phase 12 trial aims to find the best dose for children and estimate how well the combination works in these cancers. The study includes two parts phase 1 tests PEEL-224 alone or with vincristine and temozolomide to determine the recommended dose for phase 2. PEEL-224 is given on days 1 and 8 of a 21-day cycle, either by itself phase 1A or with vincristine days 1 and 8 and temozolomide days 1-5 in phase 1B and phase 2. Participants can stay on treatment for up to 24 cycles about 18 months if their disease does not worsen and side effects are manageable. Participants will have physical exams and lab tests on days 1 and 8 of each cycle. Disease response and patient-reported outcomes are checked after cycles 2, 4, 6, 9, 12, 18, and 24. In phase 1, blood samples for drug levels are taken during the first cycle. The main goals are to find dose-limiting side effects in phase 1 and measure tumor response rates in phase 2. Safety and anti-tumor activity are also monitored throughout the study.
CONDITIONS
Brief Title
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Research Team
M
Meghan Donnelly, MPH
J
James Robinson, MSW, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here